Caribou Biosciences (CRBU) Change in Account Payables (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Change in Account Payables of -$2.2 million for Q1 2026, down 258.12% year-over-year from $1.4 million in Q1 2025, and down 215.69% quarter-over-quarter from $1.9 million in Q4 2025.
Caribou Biosciences (CRBU) Change in Account Payables (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Change in Account Payables for 7 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 258.12% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$370000.0 (up 77.84% YoY), while the FY2025 annual figure was $3.3 million, up 1019.21% from the prior year.
- Change in Account Payables retreated to -$2.2 million in Q1 2026 per CRBU's latest filing, from $1.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.7 million in Q1 2024 and bottomed at -$2.4 million in Q2 2024.
- Historically, Change in Account Payables has averaged -$13058.8 across 5 years, with a median of -$153000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 5275.68% — and 2025, when it surged 937.99%.
- Caribou Biosciences' Change in Account Payables stood at -$153000.0 in 2022, then surged by 577.12% to $730000.0 in 2023, then plunged by 131.37% to -$229000.0 in 2024, then soared by 937.99% to $1.9 million in 2025, then slumped by 215.69% to -$2.2 million in 2026.
- Business Quant data shows CRBU's Change in Account Payables at -$2.2 million in Q1 2026, $1.9 million in Q4 2025, and $561000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -423,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -423,000.00 |
| Jun 30, 2026 | -423,000.00 |
| Mar 31, 2026 | -2.22 Mn |
| Mar 31, 2026 | -2.22 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 561,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Jun 30, 2025 | -630,000.00 |
| Jun 30, 2025 | -630,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | -229,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -477,000.00 |
| Sep 30, 2024 | -477,000.00 |
| Jun 30, 2024 | -2.37 Mn |
| Jun 30, 2024 | -2.37 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Mar 31, 2024 | 2.72 Mn |